Bone metastases are at the center of advanced prostate cancer care, with over 90% of patients with metastatic prostate cancer expected to have bone involvement. 1 These metastatic ...

Prostate cancer is the second most common cancer affecting men globally, with diagnostic methods and risk assessment ...

Announcing a new publication for Acta Materia Medica journal. Prostate cancer (PrCa) is the most prevalent urogenital cancer affecting men.

Evan Y. Yu, MD, discusses the therapeutic options for metastatic castration-resistant prostate cancer (mCRPC) included in the National Comprehensive Cancer Network (NCCN) guidelines, such as ...

Recently, licensed and emerging treatments for metastatic castrate-resistant prostate cancer are transforming the prognosis for men whose disease has already progressed during or after docetaxel ...

[41] While negative reelin levels were found in prostate intraepithelial ... today's lengthened survival allows metastatic foci to become clinically apparent and cancer patients are more likely ...

This follows the initial licence for treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in 2020. Following entry into a commercial agreement with Bayer ...

AI-Powered Blood Test First to Spot Earliest Sign of Breast Cancer Dec. 13, 2024 — A new screening method that combines laser analysis ... to active monitoring as treatment for ductal carcinoma ...

If you have metastatic breast cancer, you may need help from loved ones and your medical team along the way. Here’s how to ...

Do you consider the cancer measurements to be small, thus making the “observation only” protocol correct? — B.A. Dear B.A.: ...

The urine test, called MyProstateScore 2.0, or MPS2, looks at 18 different genes linked to high-grade prostate cancer. The researchers had previously demonstrated that the test was effective in ...

The FDA granted fast track designation to 64Cu-SAR-bisPSMA for PET imaging of PSMA-positive prostate cancer lesions in ...